SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/24/2017 2:41:28 PM - Followers: 148 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#4384   There's an additional hurdle with immuno-oncology drugs: sabaidii2 03/24/17 02:41:28 PM
#4383   I was wondering how long it would take The Other Guy 03/23/17 01:28:36 PM
#4382   5000 shares AH at 77c The Other Guy 03/21/17 08:42:37 PM
#4381   Geert buys in again. He must have it The Other Guy 03/20/17 04:57:43 PM
#4380   Yea, one of the lucky few the last Rubyred77 03/14/17 01:56:11 AM
#4379   We shall see if that was a great The Other Guy 03/13/17 05:45:24 PM
#4378   However, I just sold for a 15% profit. senderos 03/13/17 03:33:14 PM
#4377   You may be right. The Other Guy 03/13/17 03:27:54 PM
#4376   What are the upcoming catalysts for this stock. nomad715 03/13/17 01:35:52 PM
#4375   I keep saying this, but something significant is senderos 03/13/17 11:09:02 AM
#4374   I predict another big volume day, starting around senderos 03/13/17 10:00:08 AM
#4373   IMO, you are correct for today, but not senderos 03/10/17 07:33:40 PM
#4372   Day traders just churning shares? The Other Guy 03/10/17 04:46:51 PM
#4371   We have traded about 5.5M shares in the senderos 03/10/17 08:45:02 AM
#4370   I don't read stocktwits. It's only for traders. The Other Guy 03/09/17 02:43:16 PM
#4369   Go on Stocktwits and you'll see the reason sabaidii2 03/09/17 02:28:22 PM
#4368   Another volume surge. No explanation. The Other Guy 03/09/17 02:24:30 PM
#4367   I know that on every board there are senderos 03/08/17 08:29:05 AM
#4366   Shorts have had their way with this stock. The Other Guy 03/07/17 05:34:07 PM
#4365   Kinda feel bad for shorty here -- Going Elijah875 03/07/17 03:42:31 PM
#4364   OPK spiked at the same time as RXII The Other Guy 03/07/17 11:58:27 AM
#4363   Agree with u. As well as their being makingbiigdough 03/07/17 11:14:34 AM
#4362   Back to larger than normal volume again today. senderos 03/07/17 10:46:22 AM
#4361   I'm in today at .71! IN FOR THE makingbiigdough 03/07/17 10:31:32 AM
#4360   Yes but I'm uncertain of the carryover. A The Other Guy 03/07/17 09:02:29 AM
#4359   would this be similar to a deficit in sidslids 03/07/17 02:26:01 AM
#4358   no, i wasn't. i was thinking about sidslids 03/03/17 03:28:58 PM
#4357   Possibly, but I wouldn't know why. Institutions might The Other Guy 03/02/17 04:51:30 PM
#4356   but is it tracked by institutional investors for sidslids 03/02/17 03:25:29 PM
#4355   Accumulated deficit is the amount of loss since The Other Guy 03/02/17 10:41:54 AM
#4354   I have no idea what that $63 million sabaidii2 03/02/17 03:02:10 AM
#4353   10q "Since inception, we have incurred significant losses. Substantially sidslids 03/02/17 12:40:40 AM
#4352   "accumulated deficit = $63 million " sabaidii2 03/01/17 07:22:05 PM
#4351   accumulated deficit = $63 million sidslids 03/01/17 03:46:22 PM
#4350   More insider buying today? Let's see what senderos 03/01/17 12:27:52 PM
#4349   As a percentage of outstanding, how has it The Other Guy 02/28/17 09:22:12 AM
#4348   short interest realfast95 02/28/17 04:56:43 AM
#4347   He buys all his licensees. Should implode soon. realfast95 02/28/17 04:46:19 AM
#4346   I was wondering the same. Cash on hand The Other Guy 02/27/17 10:06:48 PM
#4345   any idea as to the new burn rate? sidslids 02/24/17 06:34:46 PM
#4344   Nice to see. Now we need some The Other Guy 02/21/17 12:14:46 PM
#4343   He and others just keep accumulating. senderos 02/21/17 08:24:43 AM
#4342   SEC form 4 just filed - CEO bought realfast95 02/21/17 07:25:56 AM
#4341   And I always hated Peanuts. Way over-rated. senderos 02/15/17 05:23:23 PM
#4340   Probably the same presentation. Different audience. realfast95 02/15/17 05:20:26 PM
#4339   And what do you thing the chance is sabaidii2 02/15/17 05:10:44 PM
#4338   conference Wednesday, February 15, 2017 - Thursday, realfast95 02/15/17 04:13:42 PM
#4337   Good point The Other Guy 02/15/17 12:28:38 PM
#4336   Cool tool, thanks. Got it. realfast95 02/15/17 11:31:28 AM
#4335   Well, I guess we learned the O/S from senderos 02/15/17 11:08:40 AM
PostSubject